Loading
A phase 1/2 trial of Zevorcabtagene autoleucel in multiple myeloma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) is a phase 1/2 interventional study registered as NCT03915184 by CARsgen Therapeutics Co., Ltd., with 105 participants planned, started 2019-09-25 and due to reach its primary completion in 2024-12-31. Interventions recorded: zevor-cel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy, Multiple myeloma.
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy.
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, CAR-T cell therapy, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, CAR-T cell therapy, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.